OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	103.54B
Revenue (ttm)	81.90B
Net Income (ttm)	10.31B
Shares Out	16.15M
EPS (ttm)	675.00
PE Ratio	9.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,860
Average Volume	35,983
Open	6,350.00
Previous Close	6,360.00
Day's Range	6,340.00 - 6,600.00
52-Week Range	4,855.00 - 10,430.00
Beta	0.47
RSI	55.78
Earnings Date	May 14, 2025

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2024, OPTUS Pharmaceutical's revenue was 81.90 billion, an increase of 13.09% compared to the previous year's 72.43 billion. Earnings were 10.31 billion, a decrease of -4.20%.